Etude : ESCAP-2020-CPHG /



ATTENTION : pour chaque essai clinique, les éléments affichés ci-dessous ne sont pas exhaustifs, et le protocole fourni par le promoteur reste l’unique document à consulter pour mener à bien un essai clinique sur centre. Pour plus d'informations, contactez le référent du territoire concerné.


Acronyme
Nom
Traitement
Type d'étude
MÀJ
Présentation de l'étude
Acronyme : ESCAP-2020-CPHG

Nom :

Traitement :

Type d'étude : Qualité de vie / Observationnelle

Dernière MÀJ : 17/06/2020
Titre
Spécialité(s)
CIM10 - Localisation(s)
Informations principales
Titre : Treatment Strategies Follow-up Implemented During the First Three Years Following Primary Lung Cancer (PLC) Diagnosed in KBP-2020-CPHG Cohort Patients

Spécialité : Organes respiratoires et intrathoraciques
Localisation : C34 - Tumeur maligne des bronches et du poumon
Schéma
Phase
Stade
Ligne(s)
Informations complémentaires
Schéma : The prognosis for primary lung cancer (PLC) is very limited. In France, patients diagnosed for PLC in 2010 and followed in Respiratory Medicine or Oncology department of a General Hospital Centre had a 5-year survival rate of 12.7% (vs 10% in 2000).

Over the last ten years, substantial improvements have been made both in terms of diagnostic (immunohistochemistry and molecular biology) and therapeutic. New treatments have been marketed and are now available in clinic.

New therapeutical strategies have been launched and have proved their efficacy in clinical studies or meta-analyses, generally increasing the survival rate of patients by a few months. However, little information still exists on the use and effectiveness of these molecules in clinical practice.

The CPHG proposes to complete the information collected during KPB-2020-CPHG study by the ESCAP-2020-CPHG study that is a follow-up of therapeutical strategies over the first 3 years of treatment. This study should improve knowledge of the PLC treatment management in General Hospital Centres.

Phase : NA

Stade : NA

NA
Informations libres de droit
Critères d'inclusion
Critères de non-inclusion
Informations libres de droit
Critères d'inclusion et de non-inclusion
Critères d'inclusion : - Age ≥ 18 years
- Primary Lung Cancer histologically (or cytologically or presence of a mutation on liquid biopsy with compatible imaging) proven between January 1st and December 31st, 2020*
- Follow-up by a lung specialist at a General Hospital
- Oral informed consent * date of collected sample

Critères de non-inclusion : - Age < 18 years
- Secondary lung cancer
- Recurrence of same histological type PLC- left to the investigator discretion according to the clinic and the imagery
- Previous enrolment in the study
- Freedom deprived patient following a legal or administrative decision
- Patient unable to give his(her) consent
NCT
Promoteur
Coordonnateur
Informations relatives au promoteur
NCT :
NCT04419155
Promoteur :
CPHG Collège des Pneumologues des Hôpitaux Généraux
Type de sponsor : Institutionnel
66, boulevard Saint-Michel
75006 PARIS 06

Coordonnateur :
Centre investigateur
Investigateur
TEC / ARC / IDE
État
MÀJ
Informations relatives aux investigateurs
Centre investigateur :
CH d'Avranches-Granville - 59 rue de la Liberté - 50300 AVRANCHES

Investigateur :
Anne-Sophie BRAVARD

TEC / ARC / IDE :

Statut de l'essai : OUVERT

MAJ : 17/06/2020